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Abstract CCAAT/enhancer-binding protein (C/EBP) isoforms
are expressed in rodent intestine and in the rat intestinal
epithelial cell line IEC-6 but their role remains to be determined.
Treatment of IEC-6 cells with the adenylate cyclase activator
forskolin led to coordinate induction of C/EBP isoforms K, L and
N at the mRNA and protein levels. Transient transfection assays
showed that their expression is controlled at the transcriptional
level. Forskolin treatment induced haptoglobin mRNA levels.
Electrophoretic mobility shift and supershift assays demon-
strated an increase in DNA-binding activities of the three C/EBP
isoforms to the haptoA and haptoC C/EBP DNA-binding sites of
the proximal haptoglobin promoter. Site-specific mutations of
both sites led to a decrease in transcriptional induction by
forskolin, suggesting that C/EBP isoforms are involved in the
cAMP-dependent regulation of the acute-phase protein gene
haptoglobin in intestinal epithelial cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
In response to in£ammation or tissue injury, several plasma
proteins known as acute-phase plasma proteins (APPs) are
induced [1]. In rat liver, haptoglobin is an APP whose syn-
thesis is increased during the acute-phase response [2]. Multi-
ple roles have been ascribed to haptoglobin including binding
and clearance of hemoglobin, inhibition of superoxide pro-
duction and stimulation of angiogenesis [1]. In hepatocytes,
transcription of haptoglobin is regulated by cytokines such as
interleukin-1 (IL-1) and interleukin-6 (IL-6) and by glucocor-
ticoids [3,4]. Analysis of acute-phase response gene promoters
in hepatocytes, including the haptoglobin promoter, has led to
the identi¢cation of regulatory elements interacting with
members of the CCAAT/enhancer-binding protein family of
transcription factors (C/EBPs) [1,2]. C/EBPs are characterized
by a leucine zipper dimerization motif enabling the formation
of homo- or heterodimers and a basic DNA-binding domain
[5]. C/EBP family members, including C/EBPK, C/EBPL and
C/EBPN, play major roles in the control of proliferation and
di¡erentiation of many cell types [6,7]. C/EBPL (NF-IL6)
and C/EBPN are involved in the cytokine-dependent transcrip-
tional activation of acute-phase response genes in hepatocytes
[2].
Human intestinal epithelial cells secrete and respond to
multiple cytokines, and are part of an acute-phase response
both in vivo and in vitro [8]. In fact, several APPs are ex-
pressed and regulated by multiple cytokines in human colon
carcinoma cell lines [9]. We have shown that the APP genes
and C/EBP isoforms are expressed in rat intestinal epithelial
cells in vivo and in vitro [10^13]. However, the regulatory
pathways and the transcription factors involved in the control
of APP gene expression in intestinal epithelial cells remain to
be determined.
In order to understand the regulatory pathways involved in
C/EBP isoform and APP gene expression in the intestinal
epithelial cell context, we have investigated the regulation of
C/EBP isoforms in response to cAMP levels and veri¢ed their
role in the regulation of the APP gene haptoglobin in the
IEC-6 cell line. This rat intestinal epithelial cell line is consid-
ered a useful in vitro model for the study of the regulation of
intestinal epithelial cell proliferation and the acute-phase re-
sponse [14^16]. We found that increases in cAMP levels lead
to coordinate induction of C/EBP isoforms, and that C/EBP
isoforms are directly involved in the cAMP-dependent regu-
lation of the APP gene haptoglobin in intestinal epithelial
cells.
2. Materials and methods
2.1. Cell culture
The rat intestinal epithelial cell line IEC-6 [17] was grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS). Twenty-four hours before stimulation, com-
plete medium was replaced with DMEM without serum. IEC-6 cells
at 80% con£uence were stimulated with forskolin (1 WM) and IBMX
(3-isobutyl-1-methylxanthine) (0.1 mM) (Sigma, St. Louis, MO).
2.2. Northern analysis
Total cellular RNAs prepared by the guanidinium isothiocyanate-
phenol method [18] were subjected to agarose gel electrophoresis with
formaldehyde and transferred to nylon membranes (Nytran, Schleich-
er and Schuell) [19]. Equal RNA loading (20 Wg) was con¢rmed by
ethidium bromide staining and by hybridization either to a rat glyc-
eraldehyde 3-phosphate dehydrogenase gene probe [20] or K-tubulin
probe [21]. Northern analysis was performed as described [22]. Hy-
bridizations were performed with the following random primed 32P-
labeled probes (Multiprime kit, Amersham): 1.8 kb rat C/EBPK frag-
ment [23]; 1.5 kb murine C/EBPL fragment [24] ; 1.0 kb murine
C/EBPN fragment [24]. The 1040 bp haptoglobin cDNA probe was
obtained by RT-PCR from IEC-6 total RNAs with the following
oligonucleotide primers: HP+1774 (5P-GAGCTGTCGTCACTCT-
CCTG-3P) and HP+4338 (5P-CAGCCCTGAACTAGTTCTTG-3P).
The nature of the ampli¢ed DNA was con¢rmed by DNA sequencing.
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Autoradiograms exposed in a linear range were quanti¢ed by densito-
metric analysis with a Pharmacia LKB XL Ultroscan and signals were
normalized to those of the control. Results are representative of three
di¡erent experiments.
2.3. Western blot analysis
Nuclei were isolated as described by Stein et al. [25]. Nuclear ex-
tracts and Western blot analysis were prepared as described previously
[11]. Proteins (20^40 Wg) resolved by SDS-PAGE were electroblotted
on nitrocellulose membranes according to Towbin et al. [26]. Incuba-
tions with a⁄nity-puri¢ed rabbit polyclonal antisera (anti-C/EBPK,
0.4 Wg/ml; anti-C/EBPL, 0.1 Wg/ml; anti-C/EBPN, 0.4 Wg/ml) (Santa
Cruz Biotechnology, Santa Cruz, CA) were performed overnight at
room temperature. The immune complexes were detected with the
Super Signal Substrate system (Pierce, Rockford, IL) according to
the manufacturer’s instructions. The intensities of the signals were
measured by densitometric analysis with a Pharmacia LKB UltroScan
and normalized to a Coomassie blue staining control for protein load-
ing. Results are representative of three di¡erent experiments.
2.4. Electrophoretic mobility shift assays
Nuclear extracts were prepared according to Stein et al. [25]. Gel
retardation assays were done as described previously [11]. Samples
were electrophoresed in a 4% polyacrylamide gel containing 0.5%
Tris-borate bu¡er and 2% glycerol. The following C/EBP-binding sites
from the rat haptoglobin promoter [3] were used for electrophoretic
mobility shift assays: haptoA, 3166 to 3145, 5P-CCAAGTAT-
GAAGCAAGAGCTCA-3P ; haptoC, 388 to 367, 5P-GCCGA-
CATTGTGCAAACACAGA-3P. Supershift assays with concentrated
C/EBP isoform rabbit polyclonal antisera (Santa Cruz Biotechnology,
Santa Cruz, CA) were performed as described previously [11].
2.5. Site-speci¢c mutagenesis of the rat haptoglobin promoter
A 396 bp portion of the rat haptoglobin promoter (3396 to 32) [3]
was inserted in the pGL3 basic luciferase reporter plasmid (Promega,
Madison, WI). Speci¢c mutations were introduced into hapto-luc at
the haptoA and haptoC nuclear factor-binding sites indicated in Fig.
5 by using oligonucleotide-directed mutagenesis [27]. Complementary
oligonucleotides containing a restriction enzyme 6 base sequence re-
placing the C/EBP-binding site core were generated. The haptoA
sequence 5P-GCCAAGTATGAAGCAAGAAGAGCTCAGCTCT-3P
(3167 to 3140) was modi¢ed in the haptoA mutant 5P-GCCAAG-
TATGACAGCTGAGCTCAGCTCT-3P and the haptoC sequence 5P-
AAGGCCGACATTGTGCAAACACAGAAAT-3P (391 to 364) in
the haptoC mutant 5P-AAGGCCGACATCAGCTGAACACAGAA-
AT-3P. These changes were based on the consensus DNA-binding sites
(underlined) for C/EBPs [28]. Double haptoA and haptoC mutants
were constructed by replacing the C/EBP haptoC site in the haptoA
mutant by a NdeI site. A mutation was also introduced in the haptoB
STAT3 DNA-binding sequence [29] 5P-CTTTGTGGTTACTGG-
AACAGTCACTGAC-3P (3125 to 397) by introducing a EcoRV
site in the haptoB mutant 5P-CTTTGTGGTTAGATATCCAGT-
CACTGAC-3. Mutations were con¢rmed ¢rst by restriction enzyme
digestion, then by DNA sequencing.
2.6. Transient transfections and luciferase assays
Transient transfections were performed with the cationic lipid Lip-
ofectin (Gibco-BRL, New York). Murine C/EBPK promoter sequen-
ces from 3355 to +7 [30], rat PCR-ampli¢ed C/EBPL promoter se-
quences from 3396 to +31 [31], and murine PCR-ampli¢ed C/EBPN
promoter sequences from 3265 to +32 were subcloned in pGL3basic
(Promega). These constructs, the hapto-luc with the single and double
haptoA and haptoC mutants, and the NF-IL6-pGL3 promoter con-
taining two copies of the NF-IL6 DNA-binding site (5P-TGA-
TTGTGCAATTGTAGATTGTGCAATGT-3P [32]), were transfected
for 7 h in IEC-6 cells. The pRL-SV40 renilla luciferase vector (Prom-
ega) was used as a transfection e⁄ciency control. After 24 h of in-
duction, cells were lysed in 300 Wl of extraction bu¡er containing
25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, 1% Triton
X-100 and 1 mM dithiothreitol. Luciferase activity was then measured
for 20 s in a Lumat LB 9507 luminometer (EGpG Berthold, USA).
The activity of renilla luciferase was used to normalize for variations
in transfection e⁄ciency. Promoter activity of each construct was ex-
pressed as ¢re£y/renilla luciferase activity ratio. Each experiment was
done three times in triplicate.
3. Results
3.1. Expression of C/EBP isoforms in response to forskolin
C/EBP family members are di¡erentially expressed in intes-
tinal epithelial cells both in vivo and in vitro [10,11]. To
understand the regulation of these transcription factors in
intestinal epithelial cells, we analyzed the e¡ect of protein
kinase A (forskolin and IBMX) activators on the expression
of C/EBP isoforms in the rat intestinal epithelial cell line IEC-
6. Forskolin treatment resulted in induction of C/EBP isoform
mRNAs with di¡erent kinetics, as determined by Northern
analysis and comparison to a GAPDH mRNA loading con-
trol (Fig. 1). C/EBPK mRNA levels increased rapidly 2.5-fold
(P6 0.05) after 1 h and remained elevated. C/EBPL mRNAs
increased rapidly and transiently with a 4.9-fold (P6 0.005)
induction after 1 h. In contrast, C/EBPN mRNA levels in-
creased later with maximal induction at 24 h (3.7-fold,
P6 0.005). Short-term induction of C/EBPK and C/EBPL
mRNAs by forskolin was still observed in the presence of
the protein synthesis inhibitor cycloheximide, suggesting that
induction of these genes did not need new protein synthesis
(data not shown). Addition of the transcription inhibitor ac-
tinomycin D to stimulated cells did not show signi¢cant in-
creased stabilities of C/EBP isoform mRNAs. The half-lives
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Fig. 1. E¡ect of forskolin on C/EBP isoform mRNA levels. Total
RNAs were isolated from IEC-6 cells treated with forskolin/IBMX
for 0, 0.5, 1, 2, 4, 12 and 24 h as indicated. Equal amounts of RNA
(20 Wg) were electrophoresed and analysed by Northern blot with
sequential hybridization of 32P-labeled C/EBPK, C/EBPL, C/EBPN
and GAPDH DNA probes. C/EBP isoform mRNA levels were
quantitated by densitometric analysis in comparison to a GAPDH
control. Means and S.E.M. were calculated with values obtained
from three independent experiments.
N. Pelletier et al./FEBS Letters 439 (1998) 275^280276
measured for C/EBPK, L and N were respectively V60, V38
and V25 min (data not shown).
To verify whether changes in C/EBP isoform mRNA ex-
pression led to modi¢cations in protein levels, we performed
Western blot experiments on nuclear proteins isolated from
IEC-6 cells stimulated with forskolin (Fig. 2). Forskolin treat-
ment resulted in increasing amounts of the C/EBPK p42 and
p30 proteins between 1 and 24 h (5.5-fold, P6 0.05). The
C/EBPL LAP and LIP proteins were induced rapidly and
transiently with 3.6-fold increases after 2 h (P6 0.005) and
3.7-fold increases after 4 h (P6 0.001). In contrast, the
C/EBPN p33 protein was induced later between 4 and 24 h
(4.7-fold, P6 0.05). These data indicate that C/EBP isoform
protein levels vary with di¡erent kinetics in response to
forskolin.
In order to determine whether C/EBP isoforms were tran-
scriptionally activated by forskolin, we subcloned the C/EBP
isoform proximal promoter regions in the pGL3basic vector.
These constructs were transfected in IEC-6 cells and luciferase
activities were measured after a 24 h induction period. For-
skolin treatment led to signi¢cant inductions from the three
promoters, respectively 3.9-fold for C/EBPK, 3.6-fold for C/
EBPL and 2.7-fold for C/EBPN (P6 0.005). Thus, C/EBP iso-
forms are di¡erently regulated by forskolin, mostly at a tran-
scriptional level. The coordinate regulation of C/EBP isoforms
by forskolin prompted us to verify the transcriptional activity
of a NF-IL6-pGL3 luciferase reporter construct. Forskolin
induced 3-fold the luciferase levels over the control values
after 24 h. These data indicate that forskolin treatment leads
to increased transactivation of a promoter containing C/EBP
DNA-binding sites in intestinal epithelial cells.
3.2. C/EBP-dependent induction of the haptoglobin gene by
forskolin
C/EBP isoforms have been implicated in vivo and in vitro
in the regulation of APP genes during the in£ammatory re-
sponse in hepatocytes [1,2]. We have suggested that C/EBPs
may play a role in the regulation of the acute-phase response
in intestinal epithelial cells. Indeed, APP genes are induced
during in£ammation in rat intestinal epithelial cells in vitro
and in vivo [12,13]. We thus veri¢ed whether targets for
C/EBPs, such as APP genes, were induced in IEC-6 cells by
forskolin. Northern analysis showed that haptoglobin
mRNAs were induced by forskolin with increasing levels until
12 h (Fig. 3).
Two major C/EBP-binding sites (haptoA and haptoC) have
been described in the haptoglobin promoter in hepatocytes [3].
In order to determine whether forskolin treatment modulated
the binding of nuclear proteins to these sites, electrophoretic
mobility shift assays were performed with nuclear extracts
isolated from IEC-6 cells stimulated with forskolin. Forskolin
treatment led to a steady increase in complex formation to
both haptoA and haptoC DNA-binding sites (Fig. 4, data not
shown). In contrast, binding to the haptoB STAT3 DNA-
binding sequence was not a¡ected (data not shown). Binding
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Fig. 3. Induction of haptoglobin by forskolin. Total RNAs were
isolated from IEC-6 cells treated with TPA or forskolin/IBMX for 4
and 12 h. Equal amounts of RNA (20 Wg) were electrophoresed and
analyzed by Northern blot with sequential hybridization of 32P-la-
beled thiostatin, haptoglobin and K-tubulin DNA probes.
Fig. 2. E¡ect of forskolin on C/EBP isoform protein levels. Nuclear
protein extracts were isolated from 0, 0.5, 1, 2, 4, 12 and 24 h for-
skolin/IBMX-treated IEC-6 cells. 50 Wg of protein extracts was ap-
plied to each lane, separated by SDS-PAGE, and transferred to ni-
trocellulose membranes for Western blotting analysis. C/EBP
isoform protein levels were quantitated by densitometric analysis in
comparison to a Coomassie blue staining control for protein load-
ing. Means and S.E.M. were calculated with values obtained from
three independent experiments.
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to the haptoA and haptoC sites was speci¢c since competition
with a 50-fold molar excess of unlabeled haptoA, haptoC and
NF-IL6 oligonucleotides resulted in a reduction in DNA-
binding activity (data not shown). We then determined the
nature of C/EBP isoforms in these complexes by supershift
assays. In non-stimulated cells, the C/EBP complex binding
both sites contained low amounts of the C/EBPK and N iso-
forms in contrast to larger amounts of C/EBPL, as assessed by
supershift and by a decrease in the intensity of the major
retarded complex (Fig. 4). Forskolin induced C/EBPK,
C/EBPN and to a lower extent C/EBPL in both complexes
after 12 h. These data show that both haptoA and haptoC
sites bind C/EBP isoforms and that forskolin treatment in-
creases C/EBP-binding activity through changes in the levels
of speci¢c isoforms interacting with both sites.
In order to determine the importance of the haptoA and
haptoC sites and the implication of C/EBP isoforms in the
regulation of the haptoglobin gene, we introduced site-speci¢c
mutations in the rat haptoglobin 3396 to +31 promoter to
inactivate the individual DNA-binding sites (Fig. 5A). The
absence of competition by cold mutated oligonucleotides in
electrophoretic mobility shift assays con¢rmed the inactiva-
tion of the haptoA and haptoC C/EBP DNA-binding sites
(data not shown). We then veri¢ed the response of the mu-
tants to forskolin in transient transfection assays. Forskolin
treatment led to 4.2-fold increases in luciferase activity of the
hapto-luc construct (Fig. 5B). Mutation of haptoA and hap-
toC respectively decreased basal activity by 30% and 50%
while inactivation of both sites decreased luciferase activity
by 70%. Individual mutations reduced the response to forsko-
lin by about 40%. Mutation of both the haptoA and haptoC
sites abolished the inducibility of the haptoglobin promoter by
forskolin (Fig. 5B). In contrast, mutation of the STAT3 hap-
toB DNA-binding sequence did not a¡ect signi¢cantly the
response of the haptoglobin promoter to forskolin. These
data show that forskolin act independently through the hap-
toA and haptoC sites. Both sites are necessary for a full tran-
scriptional response of the haptoglobin promoter to forskolin.
4. Discussion
Over the past few years, intestinal epithelial cells have been
shown to play a central role in the in£ammatory response of
the intestine [8]. However, the regulation of APP genes and
the transcription factors involved have not been clearly de-
¢ned. We show here that C/EBP isoforms and the APP
gene haptoglobin are regulated by forskolin, an adenylate
cyclase activator. Furthermore, we demonstrate that C/EBPs
are directly implicated in the cAMP-dependent regulation of
haptoglobin.
In IEC-6 cells, the three C/EBP isoforms are induced by
forskolin with di¡erent kinetics, as assessed by Northern
and Western blot analysis and transfection assays. While the
C/EBPK promoter sequences used in the transient transfection
assays do not contain a cAMP responsive element, both
C/EBPL and C/EBPN promoter sequences do [33^37]. The
rapid and transient increases in C/EBPL mRNA levels in
response to forskolin suggest a direct e¡ect of cAMP. In
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Fig. 5. The haptoA and haptoC sites are both necessary for forsko-
lin-mediated induction of haptoglobin. A: Mutations in the haptoA,
haptoB and haptoC, or both haptoA and haptoC sites were intro-
duced by replacement of the respective interacting sequence with the
restriction enzyme sequence shown in bold. B: To determine
whether these sites were involved in forskolin-dependent haptoglobin
induction, IEC-6 cells were transiently transfected with the respec-
tive mutants and the pSV40-renilla luciferase transfection control
DNA. Cells were then treated with forskolin during 24 h. Luciferase
activities were normalized to renilla luciferase activity and are ex-
pressed as fold induction in comparison to non-treated cells. Error
bars represent the standard deviations between triplicate transfec-
tions in three independent experiments. The numbers in parentheses
above bars represent the induction of luciferase activity in compari-
son to control cells. P9 0.005.
Fig. 4. Forskolin induces the DNA-binding capacity of C/EBP iso-
forms. Nuclear extracts from 0 and 12 h forskolin-treated cells were
preincubated with speci¢c antibodies against C/EBPK, C/EBPL and
C/EBPN for 30 min prior to the addition of the speci¢c haptoA and
haptoC DNA-binding site labeled oligonucleotides. The position of
the retarded complexes (C) is indicated by a bracket. The position
of the speci¢c retarded complexes is indicated (C/EBPK, *; C/EBPL,
8 ; C/EBPN, b).
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hepatocytes, CREB controls C/EBPL transcription through
two CREB sites [34]. These binding sites are probably
functional and involved in cAMP-dependent regulation of
C/EBPL in intestinal epithelial cells as well. The late appear-
ance of C/EBPN mRNAs suggest that C/EBPN is indirectly
regulated by cAMP and that the CRE-like sequences in the
proximal promoter are not recognized by CREB-like proteins.
As for C/EBPK, cAMP induces C/EBPK mRNA levels in pre-
adipocytes [38]. The speci¢c sequences in both C/EBPK and C/
EBPN promoters responsive to cAMP remain to be deter-
mined.
Forskolin treatment leads to sustained changes in C/EBP
protein levels and increases the transcriptional activity of C/
EBP DNA-binding sites containing promoters. In other cell
types, cAMP di¡erently regulates C/EBP isoform transactiva-
tion and DNA-binding activities. For example, protein kinase
A phosphorylates C/EBPL in vitro, resulting in an inhibition
of DNA binding [39]. C/EBPL is involved in the transactiva-
tion of the acetyl-CoA carboxylase in preadipocytes [38] with-
out a¡ecting DNA binding or translocation as in the rat
pheochromocytoma cell line PC12 [40]. C/EBPK, while not
phosphorylated by protein kinase A, acts as a cAMP-regu-
lated nuclear regulator of the phosphoenolpyruvate carboxy-
kinase (PEPCK) gene in hepatocytes [41,42]. Finally, C/EBPN
is involved in the cAMP-dependent regulation of the cystic
¢brosis transmembrane conductance regulator (CFTR) gene
[43] and in the activation of IGF-1 transcription in osteoblasts
[44]. Protein kinase A does not phosphorylate C/EBPN protein
[45]. It has been shown that C/EBP can heterodimerize with
CREB/activating (ATF) transcription factors [46]. This
heterodimerization leads the complex to asymmetric sequences
binding both factors. CREB proteins and C/EBP isoforms
bind asymmetric sequences in the promoter of the PEPCK
and the CFTR gene [40,42]. However, cAMP-dependent
transactivation of IGF-1 in osteoblasts and of the acetyl-
CoA carboxylase in adipocytes requires a C/EBP speci¢c
DNA-binding site [38,44].
In intestinal epithelial cells, the haptoA and haptoC sites of
the haptoglobin promoter bind C/EBP isoforms. Competition
with CRE sequences in electrophoretic mobility shift assays
did not a¡ect the binding activity (data not shown). The sites
also do not contain CRE-like sequences. Site-speci¢c muta-
genesis of both sites leads to an abolition of the forskolin-
mediated induction of the haptoglobin promoter. Co-trans-
fection of each isoform with the hapto-luc construct both in
IEC-6 and CV-1 cells results in transactivation, suggesting
that the three isoforms are involved in haptoglobin regulation
(data not shown). The changes in the ratio of each isoform
induced by cAMP should be important in the induction of the
haptoglobin gene as well as the maintenance of its expression.
cAMP could a¡ect through phosphorylation the transactiva-
tion properties of the C/EBP isoforms or the interaction of
C/EBPs with p300/CBP co-activators [47]. However, the
kinetics of accumulation of C/EBP proteins do not indicate
an e¡ect of cAMP on translocation of C/EBP proteins to the
nucleus.
In addition to C/EBPs, STAT3, a mediator of the IL-6
receptor signal, is involved in the regulation of haptoglobin
[29]. Induction of STAT3 by increased synthesis of IL-6 by
forskolin treatment could indirectly be responsible for hapto-
globin induction through an autocrine pathway. However,
our results point to a direct role of C/EBPs in forskolin-de-
pendent induction of haptoglobin. First, binding to the hap-
toB STAT3 site is not increased after forskolin treatment.
Second, mutation of the haptoB site does not a¡ect signi¢-
cantly the response of the haptoglobin promoter to forskolin,
while mutation of both haptoA and haptoC C/EBP interact-
ing sites abolishes cAMP-dependent induction. Lastly, stimu-
lation of IEC-6 cells by IL-6 does not induce the expression of
haptoglobin (data not shown). In summary, we show for the
¢rst time that C/EBP isoforms are involved in the expression
of the APP gene haptoglobin in intestinal epithelial cells and
that C/EBP isoforms participate in the transduction of signals
mediated by cAMP. Our results provide an outline of the
intricate regulation of C/EBP isoforms involved in acute-
phase protein expression.
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